Baseline characteristics and details of follow-up for patients in the UK and USA by 1L drug class
| Characteristic | Overall | 1L chemo | 1L IO monotherapy | 1L targeted therapy | ||||
| UK (n=1003) | USA (n=3819) | UK (n=698) | USA (n=2313) | UK (n=179) | USA (n=836) | UK (n=126) | USA (n=670) | |
| Proportion of study pop., % | 100 | 100 | 69.6 | 60.6 | 17.8 | 21.9 | 12.6 | 17.5 |
| Median follow-up (range*), months | 9.2 (0.0–42.7) | 9.0 (0.0–42.9) | 7.9 (0.0–42.7) | 7.3 (0.0–42.9) | 12.7 (0.1–37.3) | 8.1 (0.0–42.3) | 16.3 (0.1–37.1) | 20.3 (0.2–42.9) |
| Median age(range*), years | 68 (28–93) | 69 (21–81) | 68 (28–88) | 69 (21–81) | 67 (48–90) | 71(38–81) | 70 (32–93) | 69 (25–81) |
| Sex, n (%) | ||||||||
| Male | 541 (53.9) | 2013 (52.7) | 395 (56.6) | 1311 (56.7) | 94 (52.5) | 439 (52.5) | 52 (41.3) | 263 (39.3) |
| Female | 462 (46.1) | 1806 (47.3) | 303 (43.4) | 1002 (43.3) | 85 (47.5) | 397 (47.5) | 74 (58.7) | 407 (60.7) |
| Tumour histology, n (%) | ||||||||
| Squamous | 243 (24.2) | 957 (25.1) | 202 (28.9) | 730 (31.6) | 38 (21.2) | 210 (25.1) | 3 (2.4) | 17 (2.5) |
| Non-squamous | 641 (63.9) | 2684 (70.3) | 391 (56.0) | 1460 (63.1) | 133 (74.3) | 584 (69.9) | 117 (92.9) | 640 (95.5) |
| Not specified | 119 (11.9) | 178 (4.7) | 105 (15.0) | 123 (5.3) | 8 (4.5) | 42 (5.0) | 6 (4.8) | 13 (1.9) |
| ECOG PS score, n (%) | ||||||||
| 0–1 | 759 (75.7) | 2786 (73.0) | 513 (73.5) | 1714 (74.1) | 157 (87.7) | 556 (66.5) | 89 (70.6) | 516 (77.0) |
| 2+ | 244 (24.3) | 1033 (27.0) | 185 (26.5) | 599 (25.9) | 22 (12.3) | 280 (33.5) | 37 (29.4) | 154 (23.0) |
| EGFR status, No. (%) | ||||||||
| Mutation positive | 108 (10.8) | 556 (14.6) | 1 (0.1) | 65 (2.8) | 0 (0.0) | 11 (1.3) | 107 (84.9) | 480 (71.6) |
| Mutation negative | · | 2078 (54.4) | · | 1333 (57.6) | · | 613 (73.3) | · | 132 (19.7) |
| Unknown/missing | · | 1185 (31.0) | · | 915 (39.6) | · | 212 (25.4) | · | 58 (8.7) |
| ALK status, No. (%) | ||||||||
| Rearrangement present | 19 (1.9) | 97 (2.5) | 0 (0.0) | 8 (0.3) | 0 (0.0) | 5 (0.6) | 19 (15.1) | 84 (12.5) |
| Rearrangement not present | · | 2332 (61.1) | · | 1302 (56.3) | · | 604 (72.2) | · | 426 (63.6) |
| Unknown/missing | · | 1390 (36.4) | · | 1003 (43.4) | · | 227 (27.2) | · | 160 (23.9) |
| PDL1 status,† No. (%) | ||||||||
| PD-L1 positive | 182 (18.1) | 1486 (38.9) | 3 (0.4) | 586 (25.3) | 179 (100) | 669 (80.0) | 0 (0.0) | 231 (34.5) |
| PD-L1 negative/not detected | · | 728 (19.1) | · | 535 (23.1) | · | 39 (4.7) | · | 154 (23.0) |
| Unknown/missing | · | 1605 (42.0) | · | 1192 (51.5) | · | 128 (15.3) | · | 285 (42.5) |
This table presents variables that were common between the US and UK analyses. Additional variables that were measured in the US study only can be found in online supplemental table 2.
*Lester et al (2021) only reported range.
†In the US analysis, patients were considered PD-L1 positive if the PD-L1 tumour proportion score was≥1% or if there was a reference to PD-L1 positivity in the medical chart.
ALK, anaplastic lymphoma kinase; chemo, chemotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; IO, immunotherapy; 1L, first line; PDL1/PD-L1, programmed cell death ligand 1.